PetVivo Holdings Inc · OTC:PETV
PetVivo — Investor Presentation (March 2026)
34 slides from PetVivo's investor presentation, March 2026
Slide 1: Investor Presentation
Investor Presentation March 2026 PETV (OTCQX)
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those
Slide 3: PetVivo - Subsidiaries Org Chart
PetVivo - Subsidiaries Org Chart PetVivo Holdings, Inc. (PETV) Human Subsidiary Gel-Del Technologies, Inc. PetVivo AI, Inc. PetVivo Animal Health. Inc. Veterinary AI Product Sales (Name TBD) Manufacturer of All Human and Sales Entity for all Vet Products Human Product R&D and Sales Vet Products Enti
Slide 4: Company Highlights
Company Highlights Market Opportunity Growth Drivers +$39.8B US companion animal veterinary care and product sales market with ~ 6% Innovation historical CAGR (2020-2024)* Strategic Partnerships with experts in functional materials for innovation and product expansion of regenerative product portfol
Slide 5: Osteoarthritis (OA) Opportunity
Osteoarthritis (OA) Opportunity $39.8B Veterinary Care and Product Sales Market Osteoarthritis: Current solutions treat a common affliction symptoms, but do not of the joints manage the cause • Affects approximately 34 million • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) adult dogs and 1 million
Slide 6: Viscosupplementation
Viscosupplementation A strong hydrated biomaterial that facilitates enhanced lubrication and joint-cushioning properties. Micro-scaffolds Over time, micro-scaffolds adhere to and integrate with the existing synovial membrane. Collagen-Elastin Microparticles Porous, spongy particles absorb and releas
Slide 7: An Optimal OA Solution: Spryng with OsteoCushion Technology
An Optimal OA Solution: Spryng® with OsteoCushion® Technology ● Spryng provides a biocompatible lubricious and viscoelastic biomaterial, which promotes the restoration of joint mechanics to improve joint function ○ Similar components/function found in natural cartilage (i.e. collagen, elastin and he
Slide 8: Spryng with OsteoCushion Technology
Spryng® with OsteoCushion® Technology ● Spryng is a unique new medical device addressing the root cause of the affliction, not just the symptoms ● Purified natural components self-assemble to form an insoluble, hydrated matrix ● Protein source bovine tissues (i.e. medical grade collagen and elastin)
Slide 9: Spryng Mechanism of Action
Spryng® Mechanism of Action ● An animal suffering from osteoarthritis generally exhibits damaged and/or lost cartilage thereby creating bone on bone contact that results in an increase of joint inflammation, pain, and further loss of cartilage ● Spryng reinforces synovial membrane function, without
Slide 10: Spryng Canine Success: Cooper
Spryng® Canine Success: Cooper Condition Treatment Results¹ ● 7-year-old mixed-breed ● Immediately after ● On January 14, 2025, dog. injections a clear Cooper received Spryng® with OsteoCushion® difference in Cooper’s ● Diagnosed with severe Technology injections in mobility was seen. arthritis in b
Slide 11: Spryng Equine Success: Fergie
Spryng® Equine Success: Fergie Click to View Video Online History Exam & Diagnosis Results¹ ● 16-year-old Saddlebred ● Choppy gait in her backend, ● Mild improvement after mare. intermittent left front one week. lameness ~1 year. ● Fergie shows as a ● After one month, Saddlebred monthly and ● Grade
Slide 12: Spryng Competitive Distinctions
Spryng® Competitive Distinctions ● Outcomes address affliction/not just symptoms ● Current treatments rely on biologic activity to treat symptoms; Spryng provides structural components to address affliction ● Price/Cost advantage ● Derived from all natural materials ● Ease of application ● Vet clini
Slide 13: Spryng Product Category Comparison
Spryng® Product Category Comparison *NSAIDs: Rimadyl *Orthobiologics Arthramid Features Spryng® Librela Solensia Adequan HA/Legend Synovetin Banamine PRP, APS Noltrex Injections per Year 1 12 16-18 N/A 3-4 2-3 1 Benefits Last up to x x x 12 Months or More Bioscaffold From Naturally-Derived x Compone
Slide 14: Spryng Tolerance Studies
Spryng® Tolerance Studies Canine Tolerance Feline Tolerance Purpose: Assess tolerance of Spryng® Purpose: Assess tolerance of Spryng® administration in dogs. administration in cats. Design: 20 healthy dogs received intra-articular Design: 10 healthy female cats received intra- injection with saline
Slide 15: Spryng Clinical Studies
Spryng® Clinical Studies Six Clinical Trials Conducted To Date — All With Positive, Confirming Results Canine Hip OA Canine Stifle OA/CCL Disease Purpose: Study the effects of Collagen-Elastin Purpose: Evaluate benefit and tolerability of an intra- Hydrogel Microparticles (Spryng) on pain & function
Slide 16: New Spryng Clinical Trials
New Spryng® Clinical Trials Additional Studies 2025 - 2026 Underway or Recently Completed, Awaiting Publication Canine Study at Colorado Canine Study Canine Study State University Principal investigators: Principal investigators: Principal investigators: Felix ● Jamie Gaynor DVM, MS, ● Sherman Canap
Slide 17: No Centrifuge Required
No Centrifuge Required Freeze-dried, pooled, leukoreduced, RBC removed, allogeneic. No Blood Draw Sterility, endotoxin and mycoplasma evaluated every time. Consistent Dosing Platelet Derived Growth Factor (PDGF-BB) measured in every batch. Total platelet dose per vial equals 4 billion platelets. Con
Slide 18: What is Platelet-Rich Plasma (PRP)?
What is Platelet-Rich Plasma (PRP)? ● The most common regenerative therapy utilized in veterinary medicine. ● Concentrated preparation of platelets and plasma. ● First published use in the 1970s as an intralesional and fracture repair product in horses and dogs. ● Benefits of PRP ○ Many publications
Slide 19: Common Uses of Platelet-Rich Plasma in Veterinary Medicine
Common Uses of Platelet-Rich Plasma in Veterinary Medicine In Conjunction with Stem Cell Therapy Wound Healing Post Surgical Healing Ophthalmic Uses Dental and Oral ● Corneal Ulceration ● Keratoconjunctivitis Sicca Surgical Procedures ● Descemetocele Musculoskeletal Disease/Injury ● Osteoarthritis ●
Slide 20: State-of-the-Art Production Facilities
State-of-the-Art Production Facilities ● Spryng® product is manufactured in PetVivo’s ISO certified cleanrooms (ISO 8 to ISO 7 to ISO 5 ● Initial batch sizes of approx. 500 syringes; planning to increase to batches of 5,000+ syringes per month. ● Current production facility annual capacity is approx
Slide 21: Comprehensive IP Portfolio
Comprehensive IP Portfolio ● 12 US and Foreign Issued Patents ● Broad Claim Language - “Comprising” Transitions ● 6 Detailed Proprietary Trade Secrets ● Our Patents & Trade Secrets Protect: ○ Protein & Carbohydrate Based Thermoplastics ○ Biomaterials of Many Compositions ○ Medical, Drug Delivery & C
Slide 22: Market Overview
Market Overview Sources: American Pet Products Assoc.; North American Pet Health Insurance Association, American Horse Council, LendEDU Companion Animal/Veterinarian * Agricultural and professional equine markets not included ● US Pet Spend increased from $152B in 2024 to $157B in 2025 ● Veterinary
Slide 23: Animal Product Pipeline
Animal Product Pipeline No FDA Review or Clearance Required for Commercialization of Veterinary Medical Devices FDA clearance not required Product Commercial Particle Based Devices Species Safety Pilot Efficacy No. Launch VD-01 Osteoarthritis Canine (Spryng®) Q3 2021 VD-02 Osteoarthritis Equine (Spr
Slide 24: Human Product Pipeline
Human Product Pipeline FDA Review or Clearance Required for Commercialization of Human Medical Devices FDA clearance required Product Commercial Particle Based Devices Species Safety Pilot Efficacy No. Launch HD-01 Osteoarthritis Human (Spryng®) TBD HD-02 Osteoarthritis Human (SmartSpryng ) TBD Huma
Slide 25: Distribution Partners
Distribution Partners MWI Animal Health Covetrus MWI – PetVivo Distribution Services Covetrus – PetVivo Distribution Services Agreement Terms: Agreement Terms: ● Non-exclusive distribution agreement with ● Non-exclusive distribution agreement ongoing annual renewal option until with one year term th
Slide 26: Wholesale Partners
Wholesale Partners Vedco Clipper Vedco – Wholesaler Engagement: Clipper – Wholesaler Engagement: ● Wholesaler relationship to purchase ● Non-exclusive distribution agreement product from PetVivo and sell it to with one year term that automatically national distributors for subsequent sale renews ann
Slide 27: Digital Landia, LLC (Agentic Pet)
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Exclusive White Label License What is Agentic Pet AI? Relationship: The world's first autonomous pet care AI ecosystem that leverages cutting-edge • Exclusive white label license agreement multi-agent technology to revolutionize how between
Slide 28: Digital Landia, LLC (Agentic Pet)
Digital Landia, LLC (“Agentic Pet”) Artificial Intelligence Current Development Status Anticipated Launch Timeline and Third-Party Validation • January 2026 – Expanded B2B Beta & Readiness: : • Core multi-agent architecture completed and Expanded beta with select U.S. veterinary clinics and operatin
Slide 29: PetVivo Strategic Partners
PetVivo Strategic Partners PiezoBioMembrane, Inc. (“PBM”) and Veterinary Growth Partners (“VGP”) PBM (Functional Biomaterials) Veterinary Growth Partners (Veterinarian Association) Relationship – Master Services Agreement (Joint R&D): Relationship – Vendor Partner Agreement ● Collaboration on the re
Slide 30: Management Team Introduction
Management Team Introduction Deep Bench of Industry Veterans with Decades of Experience John Lai Garry Lowenthal John F. Dolan Bryan Monninger Josh Wilhelm CEO, President & Director CFO General Counsel VP of Sales & Distributor VP of Operations & R&D Relations Andrea Cranston Kirsty Husby, DVM, MS,
Slide 31: Strong Independent Board of Directors and Advisors
Strong Independent Board of Directors and Advisors Advisors ▪ Dr. Tracy Turner, DVM, MS, Robert Costantino Joseph Jasper Robert Rudelius Diane Levitan Dipl. ACVS, Dipl. ACSMR, Director Director Director Director Amer. Academy Thermology, AAEP Board Noble Ventures Associate Professor Long Island ▪ Dr
Slide 32: Growth Drivers
Growth Drivers Sales Growth & Expansion Regen Med Portfolio Expansion & Innovation ● US Direct Veterinary Sales Force ● PrecisePRP Canine (2/2025) PrecisePRP Equine ● 100% US veterinary market coverage via (11/2025) established distributor network. ● New Product Innovation with PiezoBioMembrane ● In
Slide 33: Company Highlights
Company Highlights Market Opportunity Growth Drivers +$39.8B US companion animal veterinary care and product sales market with ~ 6% Innovation historical CAGR (2020-2024)* Strategic Partnerships with experts in functional materials for innovation and product expansion of regenerative product portfol
Slide 34: John Lai
John Lai Chief Executive Officer jlai@petvivo.com (952) 405-6216 Spryng® with OsteoCushion Technology and PrecisePRP are exclusively sold and distributed by PetVivo Animal Health. Veterinary Use Only - Federal law restricts this device to use by or on the order of a licensed veterinarian. 844-Pet-Vi
PetVivo Holdings — Investor Presentation (March 2026) on 6ix